SGX, Third500 to build IPO market in Singapore for emerging growth companies

SINGAPORE - Third500, the Singapore-based affiliate of US investment bank, Healthios Capital Markets LLC, on Monday (Aug 27) said it is partnering the Singapore bourse to build a pre-IPO (initial public offering) and IPO market for venture-backed emerging growth companies. In particular, Third500 focuses on companies that have each attracted on average US$60 million (S$81.9 million) in private investments,

SGX, Third500 to build emerging-growth pre-IPO, IPO market

THE Singapore-based affiliate of American investment bank Healthios Capital Markets LLC is partnering the local bourse to build a pre-IPO (initial public offering) and an IPO market for emerging growth companies. The move will help create a pipeline of companies that could eventually be listed on the Singapore Exchange (SGX).

Stryker announces definitive agreement to acquire Mobius Imaging & Cardan Robotics

Kalamazoo, Michigan, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today a definitive agreement to acquire Mobius Imaging, LLC, a leader in point-of-care imaging technology, and its sister company, GYS Tech, LLC (DBA Cardan Robotics), in an all cash transaction of approximately $370 million upfront and up to $130 million of contingent payments associated with development and commercial milestones. The acquisition provides Stryker’’s Spine division with immediate entry into the intra-operative imaging segment and aligns with Stryker’’s implant and navigation offerings.

Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell

HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius Pharmaceuticals, LLC, has closed its merger with Flex Pharma, Inc.’s wholly owned subsidiary on July 19, 2019. Flex Pharma, Inc. has been renamed and will operate as Salarius Pharmaceuticals, Inc. The newly combined company will focus on the continued development of Salarius’ clinical pipeline, which targets rare, orphan cancers for which no approved targeted treatments are currently available and cancers with a high unmet need. The company will be led by Salarius’ current management team under the leadership of President and CEO, David Arthur. Former Flex Pharma President and CEO, William McVicar, Ph.D., will join Salarius’ Board of Directors. The company’s common stock will trade on the Nasdaq Capital Market under the new ticker symbol “SLRX” beginning on July 22, 2019 and will reflect the previously announced 25:1 reverse stock split that occurred effective as of the close of business on July 19, 2019.